Filtered By:
Therapy: Corticosteroid Therapy
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 66 results found since Jan 2013.
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
Int Immunopharmacol. 2023 Jun 3;120:110342. doi: 10.1016/j.intimp.2023.110342. Online ahead of print.ABSTRACTWe conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in ...
Source: International Immunopharmacology - June 5, 2023 Category: Allergy & Immunology Authors: Xavier Boumaza Margaux Lafaurie Emmanuel Treiner Ondine Walter Gregory Pugnet Guillaume Martin-Blondel Damien Biotti Jonathan Ciron Arnaud Constantin Marie Tauber Florent Puisset Guillaume Moulis Laurent Alric Yves Renaudineau Dominique Chauveau Laurent S Source Type: research
Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study
CONCLUSION: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.PMID:36763798 | DOI:10.1093/bjd/ljac118
Source: The British Journal of Dermatology - February 10, 2023 Category: Dermatology Authors: Khalaf Kridin Noor Mruwat Kyle T Amber Ralf J Ludwig Source Type: research
A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial
CONCLUSION: Results suggest potential efficacy with the NTHi-Mcat vaccine against severe exacerbations in certain patients with COPD, in particular those who have frequent exacerbations and use inhaled corticosteroids. This potential signal requires confirmation in an appropriately designed prospective clinical trial.TRIAL REGISTRATION: ClinicalTrials.gov, NCT03281876.PMID:36068109 | DOI:10.1016/j.vaccine.2022.08.053
Source: Vaccine - September 6, 2022 Category: Allergy & Immunology Authors: Ashwani K Arora Kenneth Chinsky Claus Keller Irvin Mayers Sergi Pascual-Guardia Merc è Pérez Vera Christophe Lambert Stefano Lombardi Simona Rondini Sun Tian Fernando Ulloa-Montoya Luca Moraschini Daniela Casula NTHi-Mcat-002 study group Source Type: research
The comparison of exacerbation and pneumonia before and after conjugated pneumococcal vaccination in patients with chronic obstructive pulmonary disease, and the effect of inhaled corticosteroid use on results
CONCLUSIONS: This study revealed that PCV13 provides a significant decrease in both exacerbation and pneumonia episodes in COPD patients. On the other hand, the use of ICSs and the types of ICSs were not found to have adverse effects on pneumonia and acute exacerbations in vaccinated COPD patients.PMID:35785879 | DOI:10.5578/tt.20229805
Source: Tuberkuloz ve Toraks - July 5, 2022 Category: Respiratory Medicine Authors: G örkem Vayısoğlu Şahin G ülistan Karadeniz G ülru Polat Enver Yaln ız Aysu Ayranc ı Fatma Demirci Üçsular Mutlu Onur G üçsav Source Type: research
